# US 11,299,491 B2 · Synthesis of key intermediate of KRAS G12C inhibitor compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,299,491 B2
- Document ID: US11299491B2
- Status: Granted
- Kind: B2
- Application number: 16/685,841
- Filed: 2019-11-15
- Published: 2020-07-09
- Granted: 2022-04-12
- Earliest claimed: 2018-11-16
- Assignees: Amgen Inc.
- Applicants: Amgen Inc.
- Inventors: Andrew Thomas Parsons; Brian McNeil Cochran; William Powazinik, IV; Marc Anthony Caporini
- Web page: https://patentgrep.com/patent/US11299491B2

## CPC

- C07D 471/04: Ortho-condensed systems
- C07C 69/76: Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C 309/24: of a carbon skeleton containing six-membered aromatic rings
- C07B 57/00: Separation of optically-active compounds
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure useful for the synthesis of compounds that target KRAS G12C mutations, such as

## Claims

### Claim 1

A compound, wherein the compound is: